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Objective: To investigate the effect of breastfeeding on the change of visfatin levels in postpartum
women.
Materials and methods: Twenty-nine postpartumwomenwere enrolled into the study. All measurements
were completed at the 2nd and 16th week postpartum. Women who had been continuously breastfeeding
(10 women), those who had never breastfed (9 women) and those who had breastfed for a short period
of time but then ceased (10 patients) were enrolled into the study. Serum levels of insulin, glucose,
cholesterol, triglycerides, and visfatin were measured.
Results: In the continuously breastfeeding group, the women at the 16-week point had higher levels of
visfatin (14.5 ± 4.1, 17.0 ± 5.1 ng/mL; p ¼ 0.001). In the never breastfed group, the women at the 16-week
point had higher levels of visfatin (22.6 ± 3.9, 19.1 ± 3.0 ng/mL; p ¼ 0.005). The visfatin levels in the
breastfed but ceased group were found to not be signiﬁcantly different between the two test points
(13.3 ± 2.5, 13.4 ± 2.5 ng/mL; p ¼ 0.815). Regarding the association between serum visfatin and markers
of lipid metabolism, signiﬁcant correlations were found between visfatin and hemoglobin A1c
(r ¼ 0.425, p ¼ 0.022) at the 2-week point and triglycerides (r ¼ 0.387, p ¼ 0.038) at the 16th week.
Conclusion: Continuous breastfeeding for at least 16 weeks could induce increasing visfatin levels. The
ﬁndings of our study might shed light on the necessity of further exploration of the mechanisms through
which lactation may inﬂuence the occurrence of diabetes.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Visfatin, known as a pre-B cell colony-enhancing factor or
nicotinamide phosphoribosyltransferase (Nampt), is a 52-kDa
protein originally isolated as a secreted factor. Visfatin synergizes
with interleukin-7 and stem cell factors to promote the growth of B
cell precursors [1]. More recently, visfatin has been identiﬁed as an
adipokine, predominantly expressed in and secreted from visceral
adipose tissue while exerting a number of insulin-mimetic effects
[2]. The elevation in visfatin concentration has been found in
obesity, insulin resistance states, type 2 diabetes mellitus (DM), and
polycystic ovary syndrome (PCOS) [3e8]. These studies suggested
that increased visfatin inwomenwith PCOS and severe obesity mayand Gynecology, Kaohsiung
oad, Kaohsiung 807, Taiwan,
n).
bstetrics & Gynecology. Publishedbe a compensatory response to insulin resistance [9,10]. Some
studies, however, have shown contradictory results: visfatin levels
were found to be reduced inwomenwith type 2 DM and thosewith
gestational DM [11e13]. These results suggested that a decrease in
serum visfatin levels could be related to the failure of glucose
homeostasis.
Lactation imposes a substantial metabolic burden and total
energy expenditure on mothers [14,15]. Lactation may attenuate
adverse metabolic risk factor changes that occur with pregnancy
and therefore might affect a woman's future risk of cardiovascular
and metabolic diseases. Duration of lactation and sustained
lactation-associatedmetabolic changes were found to be associated
with reduced incidence of type 2 DM [16e18]. Prolonged lactation
was associated with a “lasting protective effect” on insulin secre-
tion [19]. A study by McManus et al showed that lactating women
did have a higher disposition index, indicating more efﬁcient
pancreatic b cell function [20]. The relationship between lactation
and metabolic risk factors may be related to higher energy use or
other effects on metabolism [21]. However, mechanisms thatby Elsevier Taiwan LLC. All rights reserved.
Table 1
Clinical data of the “feeding” group.
Feeding
2nd wk (n ¼ 10) 16th wk (n ¼ 10) p
Age (y) 32.8 ± 3.9
Body weight (kg) 60.2 ± 7.2 58.3 ± 6.1 0.005**
BMI (kg/m2) 24.1 ± 2.5 23.4 ± 2.1 0.005**
AST (IU/L) 19.6 ± 5.5 19.3 ± 4.7 0.790
ALT (IU/L) 25.1 ± 12.7 21.7 ± 7.4 0.281
BUN (mg/dL) 15.0 ± 3.4 12.8 ± 3.3 0.041*
Creatinine (mg/dL) 0.6 ± 0.1 0.6 ± 0.1 0.103
Insulin (mIU/mL) 3.5 ± 2.9 3.1 ± 1.4 0.721
Glucose (AC) (mg/dL) 88.0 ± 14.5 91.6 ± 5.1 0.434
Cholesterol (mg/dL) 235.6 ± 50.8 198.7 ± 28.8 0.044*
Triglycerides (mg/dL) 94.9 ± 35.1 63.2 ± 37.3 0.043*
Hemoglobin A1c (%) 5.4 ± 0.3 5.4 ± 0.3 0.591
Visfatin (ng/mL) 14.5 ± 4.1 17.0 ± 5.1 0.001**
Values are expressed as mean ± standard deviation. “Feeding” refers to women who
had been continuously breastfeeding.
*p < 0.05, **p < 0.01.
ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; BMI ¼ body
mass index; BUN ¼ blood urea nitrogen.
Table 2
Clinical data of the “stopped feeding” group.
Stopped feeding
2nd wk (n ¼ 10) 16th wk (n ¼ 10) p
Age (y) 30.4 ± 4.2
Body weight (kg) 58.1 ± 8.1 56.2 ± 8.4 0.027*
BMI (kg/m2) 23.0 ± 1.8 22.2 ± 2.0 0.026*
AST (IU/L) 20.5 ± 3.6 20.2 ± 3.7 0.790
ALT (IU/L) 24.6 ± 6.9 21.1 ± 5.4 0.144
BUN (mg/dL) 12.9 ± 3.7 10.3 ± 2.8 0.085
Creatinine (mg/dL) 0.6 ± 0.1 0.6 ± 0.1 0.514
Insulin (mIU/mL) 3.2 ± 1.6 3.8 ± 2.0 0.335
Glucose (AC) (mg/dL) 91.0 ± 13.9 92.4 ± 9.7 0.535
Cholesterol (mg/dL) 231.8 ± 34.5 180.5 ± 26.6 <0.001**
Triglycerides (mg/dL) 89.4 ± 67.3 81.0 ± 62.6 0.191
Hemoglobin A1c (%) 5.1 ± 0.5 5.2 ± 0.4 0.460
Visfatin (ng/mL) 13.3 ± 2.5 13.4 ± 2.5 0.815
Values are expressed as mean ± standard deviation. “Stopped feeding” refers to
those who breastfed for a short period of time but then ceased.
*p < 0.05, **p < 0.01.
ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; BMI ¼ body
mass index; BUN ¼ blood urea nitrogen.
Table 3
Clinical data of the “no feeding” group.
No feeding
2nd wk (n ¼ 9) 16th wk (n ¼ 9) P
Age (y) 31.2 ± 3.3
Body weight (kg) 60.5 ± 6.8 56.3 ± 5.6 0.012*
BMI (kg/m2) 23.8 ± 2.8 22.2 ± 2.5 0.012*
AST (IU/L) 19.2 ± 2.1 18.7 ± 3.3 0.594
ALT (IU/L) 20.6 ± 7.3 16.3 ± 4.3 0.111
BUN (mg/dL) 14.5 ± 3.3 11.3 ± 1.9 0.004**
Creatinine (mg/dL) 0.6 ± 0.1 0.6 ± 0.1 0.377
Insulin (mIU/mL) 2.7 ± 1.2 3.3 ± 1.0 0.107
Glucose (AC) (mg/dL) 89.7 ± 5.3 91.2 ± 3.9 0.607
Cholesterol (mg/dL) 238.3 ± 51.9 188.0 ± 31.1 0.015*
Triglycerides (mg/dL) 83.2 ± 46.8 76.0 ± 33.3 0.622
Hemoglobin A1c (%) 5.1 ± 0.3 5.2 ± 0.3 0.347
Visfatin (ng/mL) 22.6 ± 3.9 19.1 ± 3.0 0.005**
Values are expressed as mean ± standard deviation. “No feeding” refers to those
who had never breastfed.
*p < 0.05, **p < 0.01.
ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; BMI ¼ body
mass index; BUN ¼ blood urea nitrogen.
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of type 2 DM are still unclear. Because visfatin has been suggested
to exert protective effects on pancreatic b cell function, we hy-
pothesize that the breastfeeding-related physiological changes in-
ﬂuence serumvisfatin levels. The objective of the current studywas
to investigate: (1) the change of visfatin levels in breastfeeding in
postpartum women, and (2) the correlation of visfatin levels with
insulin resistance, glucose, and lipid levels.
Methods
Twenty-nine postpartum women were enrolled into the study.
According to their breastfeeding status, they were divided into
three groups: women who had been continuously breastfeeding
(10 patients); those who had never breastfed (9 patients); and
those who had breastfed for a short period of time but then ceased
(10 patients). Blood samples were obtained directly from a can-
nulated vein on the 2nd week and the 16th week postpartum. The
serum was separated by centrifugation and stored at 20C until
further analysis. Serum visfatin concentration was analyzed using
an enzyme immunosorbent assay according to the manufacturer's
instructions (Phoenix Pharmaceuticals, Belmont, CA, USA). The
intra-assay and interassay coefﬁcients of variation were 5.5% and
10.1%, respectively. Glucose, hemoglobin A1c, blood urea nitrogen
(BUN), creatinine, aspartate aminotransferase (AST), alanine
aminotransferase (ALT), total cholesterol, and triglycerides were
analyzed using LX-20 pro chemistry analyzers (Beckman Coulter,
Brea, CA, USA). Insulin was measured using a Coat-A-count radio-
immunoassay kit (Diagnostic Products Corp, Los Angeles, CA, USA).
All women were of Han Chinese origin and delivered and had
follow-up visits at the Department of Obstetrics at the Kaohsiung
Medical University Hospital. The women were in good health and
had not used medications known to affect sex hormones, lipids, or
carbohydrate metabolism. Women who had children with fetal
anomalies, or who had thyroid disease, preexisting hypertension,
DM, or other chronic diseases were excluded from the study. A
precise medical history, including body mass index (BMI), was
obtained. The approval of the institutional review board (IRB) was
obtained and the consent procedure was approved by the Ethics
Committee of Kaohsiung Medical University Hospital. Written
informed consent was received from all participants involved in the
study.
Data were evaluated using SPSS software for Windows (version
12.0; SPSS Inc, Chicago, IL, USA) and presented as mean ± standard
deviation. Differences between two points were evaluated using a
paired t test. Pearson correlation and linear univariate analysis
were carried out to determine the relationship between the vari-
ables. All tests were two-tailed, and the signiﬁcance level was
deﬁned as p < 0.05.
Results
The clinical features are shown in Tables 1e3 for the three
groups. There were no major differences between the two time
points (2nd week and 16th week postpartum) with respect to the
levels of AST, ALT, creatinine, glucose, insulin, and hemoglobin A1c
in all three groups. The patients at the 16-week point had lower
levels of cholesterol, body weight, BMI, and BUN in all three groups.
However, only the continuously breastfeeding group had lower
levels of triglycerides at the 16-week point. In the continuously
breastfeeding group, the women at the 16-week point had higher
levels of visfatin (14.5 ± 4.1, 17.0 ± 5.1 ng/mL; p ¼ 0.001). In the
never-breastfed group, the patients at the 16-week point had
higher levels of visfatin (22.6 ± 3.9, 19.1 ± 3.0 ng/mL; p ¼ 0.005).
The visfatin levels in the breastfed but ceased group were found
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(13.3 ± 2.5, 13.4 ± 2.5 ng/mL; p ¼ 0.815).
The results of a linear univariate analysis of the association be-
tween serumvisfatin, markers of glucose and lipid metabolism, and
biochemical index are presented in Table 4. The correlations be-
tween visfatin and AST, ALT, BUN, creatinine, insulin, glucose,
cholesterol, age, BMI, and body weight were not statistically sig-
niﬁcant. Regarding the association between serum visfatin and
markers of lipid metabolism, signiﬁcant correlations were found
between visfatin and hemoglobin A1c (r¼0.425, p¼ 0.022) at the
second week point and triglycerides (r ¼ 0.387, p ¼ 0.038) at the
16th week.
Discussion
The major ﬁnding of this study is that when comparing women
who had continuously been breastfeeding with those who had
never breastfed, visfatin increased in the former group but
decreased in the latter between the two test points. The visfatin
levels in the group who had breastfed for a short period of time but
then ceased were found to have no signiﬁcant difference between
the two test points. To the best of our knowledge, literature
regarding changes in visfatin levels in postpartum breastfeeding
women is extremely limited. Malamitsi-Puchner's [22] study indi-
cated that the rapid decrease of blood visfatin concentrations in
postpartumwomen on the 1st day after birth could be attributed to
the elimination of its secretion by the placenta and fetal mem-
branes. Bienertova-Vasku's [23] study showed a similar trend, but
with visfatin levels reaching a stable level after 12e14 days post-
partum. According to these studies, our study compared visfatin
levels in the 2nd week and the 16th week postpartum when the
effects from placenta and fetal membranes have ended. Bienertova-
Vasku's [23] study demonstrated that visfatin levels in maternal
serum expressed a signiﬁcant tendency toward a steady decrease
during the entire period of 180 days after delivery. In Bienertova-
Vasku's study, they did not show if they stratiﬁed the study par-
ticipants according to their breastfeeding status, and furthermore,
there were different case numbers at each test point. Our study
participants were divided into three groups based on their different
breastfeeding status.We followed upwith the same case number at
both time points. Bienertova-Vasku's study suggested that visfatin
is abundantly secreted into breast milk in humans, reaching
approximately 100-fold higher concentrations compared with the
maternal serum [23]. Yonezawa et al's [24] study demonstrated
that mammary epithelial cells were responsible for the expression
and secretion of visfatin protein into breast milk. Visfatin mightTable 4
Correlations between serum visfatin concentrations and various parameters.
Visfatin (2nd wk) Visfatin (16th wk)
r p r p
Age 0.231 0.228 0.156 0.420
Body weight 0.261 0.171 0.090 0.644
BMI 0.212 0.269 0.096 0.620
Insulin 0.100 0.605 0.218 0.255
Glucose (AC) 0.223 0.244 0.257 0.179
Hemoglobin A1c 0.425 0.022* 0.224 0.242
AST 0.092 0.636 0.255 0.182
ALT 0.105 0.588 0.272 0.154
BUN 0.255 0.182 0.174 0.365
Creatinine 0.005 0.980 0.195 0.312
Cholesterol 0.127 0.511 0.026 0.893
Triglycerides 0.226 0.238 0.387 0.038*
*p < 0.05.
ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; BMI ¼ body
mass index; BUN ¼ blood urea nitrogen.play an important role in mammary epithelial cells and mammary
glands. Secretory epithelial cells may also be the source of visfatin
in both breast milk and maternal serum.
Although the mechanism that underlies the preventative role of
breastfeeding for diabetes has not been very clear to date, the in-
crease in circulating cytokines, free fatty acids, and persistent hy-
perglycemia during the progression of type 2 diabetes were found
to be associated with the failure of b-cell function and b-cell mass
reduction [25]. Recent studies showed that visfatin functions as an
intracellular and extracellular nicotinamide adenine dinucleotide
(NAD) biosynthetic enzyme and maintains the systemic NAD pool
to a certain extent [26]. Visfatin-mediated systemic NAD biosyn-
thesis plays a critical role in the regulation of b-cell function [26,27].
Downregulation of visfatin expression in Fao cells is associatedwith
signiﬁcantly reduced NAD biosynthesis and signiﬁcantly decreased
incremental glucose uptake after stimulation with insulin [28].
Therefore, our study might shed light on the necessity of further
exploration of the mechanisms through which lactation may in-
ﬂuence the occurrence of diabetes.
Our study found that there was no signiﬁcant change in insulin
concentration. The reason that the change was not signiﬁcant is
likely due to the limited time of the study. In addition, the partic-
ipants in this study are normal pregnant women who could prop-
erly control their insulin level. McManus et al [20] found no
signiﬁcant differences in insulin sensitivity, glucose effectiveness,
visceral fat, or subcutaneous fat from 26 white women with
gestational diabetes at 3 months postpartum, but lactating women
did have a higher disposition index, indicating more efﬁcient
pancreatic b-cell function [20]. Visfatin release may be related to
nutrient availability and cellular bioenergetics and is down-
regulated by overfeeding [29]. Under normal physiologic condi-
tions, visfatin does not appear to control glucose metabolism but
may play a regulatory role in lipid metabolism [30]. In our study,
triglyceride levels did not show a signiﬁcant decrease in post-
partum women who had never breastfed but signiﬁcantly
decreased in the ones who had continuously breastfed between the
two test points. Lipid proﬁle changes during the puerperium were
reported to include rapid declines in triglyceride levels [15,31,32].
Triglyceride levels declined more rapidly in lactating than that of
nonlactating women within 20 weeks postpartum and stabilizing
thereafter [33,34]. The correlation between visfatin and triglyceride
levels is inconsistent. Statistically signiﬁcant inverse correlations
were observed between serum visfatin and triglyceride [35,36]. A
positive association between visceral adipose tissue visfatin
messenger RNA level and plasma triglyceride was found [37]. The
circulating visfatin concentration was found to be positively asso-
ciated with plasma triglyceride level in children with obesity and
young healthy men [4,30]. Whether rapid decline of triglyceride in
women with breastfeeding contributes to elevated visfatin needs
further investigation.
In our study, whether weight loss contributed to the increase of
visfatin was also considered. Weight loss caused by breastfeeding
was discussed as a possible factor but was not found to reduce the
risk of type 2 DM [17]. Discussions on whether weight loss would
affect blood visfatin vary [38]. Some studies have found that weight
loss can result in a decrease in fat cells and therefore a decrease in
visfatin levels [39e41]; some studies, however, found that increase
in visfatin is related to weight loss [42e44]. In our study, both
postpartum women with continuous or no breastfeeding had lost
weight in the 14-week period. As observed in our study, weight loss
was unlikely to be contributory to the inverse association between
breastfeeding and visfatin levels.
In conclusion, continuous breastfeeding for at least 16 weeks
could induce increasing visfatin levels. The ﬁndings of our study
might shed light on the necessity of further exploration of the
C.-J. Shen et al. / Taiwanese Journal of Obstetrics & Gynecology 54 (2015) 217e220220mechanisms through which lactationmay inﬂuence the occurrence
of diabetes.
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